Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Astrana HealthASTH 87 3-Year Revenue Growth Rate is 37.00% as of Jun. 2026, which is 6% above its 10-year median of 34.90. GuruFocus rates ASTH with a GF Score™ of 87/100 and a GF Value™ of $66.24 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 612 Healthcare Providers & Services companies, Astrana Health ranks better than 91.5% on this metric.
During the past 12 months, Astrana Health's average Revenue per Share Growth Rate was 56.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 37.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 42.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 23.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Astrana Health was 62.10% per year. The lowest was 1.30% per year. And the median was 34.90% per year.
Astrana Health (NAS:ASTH) 3-Year Revenue Growth Rate Explanation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Astrana Health 3-Year Revenue Growth Rate Related Terms
ASTH vs SNDA, SGRY, ADUS: 3-Year Revenue Growth Rate Comparison
For the Medical Care Facilities subindustry, Astrana Health's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astrana Health 3-Year Revenue Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Astrana Health's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Astrana Health's 3-Year Revenue Growth Rate falls into.
Astrana Health 3-Year Revenue Growth Rate Calculation
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
What does a 3-Year Revenue Growth Rate of 37.00% mean?
Astrana Health (ASTH) has a 3-Year Revenue Growth Rate of 37.00% as of Jun. 2026. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Astrana Health and its competitors. This is near median its historical median of 34.90. Over the past decade, Astrana Health's 3-Year Revenue Growth Rate has ranged from 1.30 to 62.10. According to the industry distribution chart, Astrana Health ranks #52 out of 612 companies in the Healthcare Providers & Services industry, placing it in the top 8.5%.
Is Astrana Health's 3-Year Revenue Growth Rate too high?
Astrana Health's current 3-Year Revenue Growth Rate of 37.00% is near median its 10-year median of 34.90. Over the past 10 years, this metric has ranged from a low of 1.30 to a high of 62.10. The Healthcare Providers & Services industry median 3-Year Revenue Growth Rate is 6.95. Astrana Health's value of 37.00% is 432.4% above this industry median. Based on the distribution chart, Astrana Health ranks #52 out of 612 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Astrana Health has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Astrana Health's 3-Year Revenue Growth Rate compare to SNDA and SGRY?
According to the Healthcare Providers & Services industry distribution chart, Astrana Health ranks #52 out of 612 companies for 3-Year Revenue Growth Rate. This places Astrana Health in the top 9% of its industry — outperforming the majority of peers. The industry median 3-Year Revenue Growth Rate is 6.95. Astrana Health's value of 37.00% is 432.4% above this benchmark. Historically, Astrana Health's own 3-Year Revenue Growth Rate has ranged from 1.30 to 62.10 over the past decade. While the company's 10-year median is 34.90 vs. the industry median of 6.95, Astrana Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Healthcare Providers & Services company?
The median 3-Year Revenue Growth Rate among Healthcare Providers & Services companies is 6.95, based on 612 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astrana Health's current 3-Year Revenue Growth Rate of 37.00% is 432.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Astrana Health and its competitors. For the Healthcare Providers & Services industry, the median 3-Year Revenue Growth Rate is 6.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astrana Health's current 3-Year Revenue Growth Rate is 37.00%, which is near median its own 10-year median of 34.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astrana Health stock overvalued right now?
Based on GuruFocus' analysis, Astrana Health (ASTH) is currently considered Significantly Undervalued. The stock's GF Value™ is $66.24, compared to a current price of $33.55 — trading 49.4% below its estimated fair value. The current 3-Year Revenue Growth Rate is 37.00%, which is near median its 10-year median of 34.90 and 432.4% above the Healthcare Providers & Services industry median of 6.95. Astrana Health's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For Astrana Health (ASTH), the current 3-Year Revenue Growth Rate is 37.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astrana Health (ASTH) Overvalued in 2026?
Based on GuruFocus' analysis, Astrana Health stock appears to be undervalued.
The current stock price of $33.55 is trading 49.4% below its estimated GF Value™ of $66.24.
GuruFocus considers Astrana Health to be Significantly Undervalued.
Key valuation signals for ASTH:
3-Year Revenue Growth Rate: 37.00% (near median its 10-year median of 34.90)
GF Value™: $66.24 vs. price of $33.55 (49.4% below fair value)
Industry Position: 432.4% above the Healthcare Providers & Services median (#52 of 612)
No single metric tells the full story. See the ASTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
87GF Score
Get the complete analysis for ASTH
3-Year Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASTH has been successfully added to your 
